Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock Drops
Johnson & Johnson reported a 96% drop in Q3 net earnings due to a special charge related to talc litigation, despite a 5.9% sales increase. The company raised its FY26 adjusted EPS guidance to $11.10 and announced a $1.34 quarterly dividend. Shares fell 2.6% in pre-market trading.
How this was made
The 30-second read
Why it matters
The earnings miss and litigation charge drive immediate negative sentiment, while the guidance lift offers a longer‑term upside narrative.
Market read
Large‑cap pharma earnings with mixed signals; immediate downside risk but potential for later recovery on guidance.
What to watch
The special charge is one‑time; underlying sales grew 5.9% YoY, indicating operational strength.
Background
Johnson & Johnson disclosed a special charge related to pending talc litigation and announced a $1.34 quarterly dividend.
Ticker impact
Johnson & Johnson reported Q3 profit down 96% to $210M and raised FY26 adjusted EPS guidance to $11.10, while shares fell ~2.6% pre‑market.
likely downside pressure as the market prices in the profit miss and litigation charge
The surprise profit decline and one‑time charge dominate the news; the guidance increase is modest and may not offset the negative reaction.
Market effects
Healthcare sector may see slight pullback as a major pharma beats expectations on guidance but misses earnings.
U.S. markets could open lower on the news, especially large‑cap defensive stocks.
Limited to U.S. investors; global markets may watch for broader pharma earnings trends.
Counterpoint
The modest guidance raise could support a short‑term bounce if investors focus on the upside outlook rather than the profit miss.
Key entities
- CompanyJohnson & Johnson
Global healthcare conglomerate reporting Q3 results.
